Log in

Relevant bibliographies by topics / Lucentini / Journal articles

To see the other types of publications on this topic, follow the link: Lucentini.

Journal articles on the topic 'Lucentini'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lucentini.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gómez Cadenas, Juan José, and Marco Guagnelli. "Babel Revisitada." EU-topías. Revista de interculturalidad, comunicación y estudios europeos 22 (December 30, 2021): 37. http://dx.doi.org/10.7203/eutopias.22.22924.

Full text

Abstract:

En 1997, Iván Almeida, catedrático del Borges Center en Aarhus, escribe a Umberto Eco, haciéndole notar un aparente error en un reciente artículo suyo. Eco, copiando verbatim la traducción del emintente Lucentini, asevera que las galerías de la famosa Biblioteca de Babel, constan de «veinticinco estantes, a razón de cinco por lado, que cubren todos los lados menos uno», mientras que en la versión original, Borges asegura que «veinte estantes, a razón de cinco por lado, cubren todos los lados menos dos». Y eso no es todo. En la traducción de Lucentini se lee que cada uno de los volúmenes de la

APA, Harvard, Vancouver, ISO, and other styles

2

Matula, Jozef. "De sex rerum principiis. Hermes Trismegistus , Paolo Lucentini , Mark D. Delp." Speculum 83, no. 3 (2008): 709–10. http://dx.doi.org/10.1017/s0038713400014962.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sobol, Peter G. "Paolo Lucentini, ed., Liber Alcidi de immortalitate animae: Studio e edizione critica. Naples: Istituto Universitario Orientale, Dipartimento di Filosofia e Politica, 1984. Paper. Pp. cix, 154." Speculum 62, no. 03 (1987): 773. http://dx.doi.org/10.1017/s0038713400123292.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

MECHCATIE, ELIZABETH. "Atripla, Lucentis." Skin & Allergy News 37, no. 9 (2006): 50. http://dx.doi.org/10.1016/s0037-6337(06)71537-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

MECHCATIE, ELIZABETH. "Atripla, Lucentis." Internal Medicine News 39, no. 15 (2006): 5. http://dx.doi.org/10.1016/s1097-8690(06)73916-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

MECHCATIE, ELIZABETH. "Atripla, Lucentis." Family Practice News 36, no. 15 (2006): 48. http://dx.doi.org/10.1016/s0300-7073(06)73624-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Azanza, B., and P. Montoya. "A new deer from the lower Turolian of Spain." Journal of Paleontology 69, no. 6 (1995): 1163–75. http://dx.doi.org/10.1017/s0022336000038142.

Full text

Abstract:

A new genus and species of deer, Lucentia iberica, is described from the lower Turolian (MN 11) locality of Crevillente 2 (Alicante province, Spain). Eostyloceros pierensis Thomas, 1951 from Piera (Barcelona province) is also included in the new genus. The two-tined Lucentia is not a representative of Muntiacinae. From the emplacement on the cranial cavity and moderate backward inclination of the pedicles, and from the monopodial construction of the antlers, Lucentia is probably the sister group of the clade Cervinae + Odocoileinae. The hypothesis that Lucentia is most closely related to Cervi

APA, Harvard, Vancouver, ISO, and other styles

8

Godlee, F. "Avastin versus Lucentis." BMJ 344, may02 2 (2012): e3162-e3162. http://dx.doi.org/10.1136/bmj.e3162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Putiienko, O. O. "Results of Anti-VEGF Therapy in the Treatment of Post-vitrectomy Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy." International scientific-practical journal Ophthalmology, no. 1 (12) (2021): 97–103. http://dx.doi.org/10.30702/ophthalmology31032021-12.1.97-103/215-085.

Full text

Abstract:

Post-vitrectomy vitreous hemorrhage in patients with proliferative diabetic retinopathy (PDR) occurs in up to 75% of cases, and this highlights the need to search for new treatment options. The aim. To analyze the results of anti-VEGF therapy in the treatment of post-vitrectomy vitreous hemorrhage in patients with PDR. Materials and methods. Seventy-eight patients (78 eyes) were examined. Twenty patients (20 eyes) of the control group underwent outpatient ﬂuid gas exchange (OFGE) with 20% gas-air mixture of perﬂuoropropane for the treatment of post-vitrectomy vitreous hemorrhage. The first mai

APA, Harvard, Vancouver, ISO, and other styles

10

Marco, J. Alberto, Juan F. Sanz-Cervera, Vicente García-Lliso, and Natalia Batlle. "Sesquiterpene lactones from Artemisia lucentica." Phytochemistry 45, no. 4 (1997): 755–63. http://dx.doi.org/10.1016/s0031-9422(97)00029-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Zhaivoronok, N. S., V. V. Egorov, G. P. Smoliakova, et al. "Analysis of effectiveness of angiogenesis inhibitor in treatment of choroidal neovascularization in patients with chronic central serous chorioretinopathy." Modern technologies in ophtalmology, no. 1 (May 29, 2021): 163–66. http://dx.doi.org/10.25276/2312-4911-2021-1-163-166.

Full text

Abstract:

Purpose. To evaluate efficacy of angiogenesis inhibitor ranibizumab (Lucentis, Novartis, Switzerland) in treatment of choroidal neovascularization (CNV) in patients with chronic central serous chorioretinopathy (CSCR). Material and methods. The object of study was 11 patients (8 men and 3 women, 11 eyes) aged from 41 to 50 years with CNV on the background of chronic CSCR. All monitored patients underwent 3 consecutive “loading” intravitreal Lucentis injections is either 0.5 mg in 0.05 mL once a month. Results. After 3 months, all studied patients had complete obliteration of CNV. At the same t

APA, Harvard, Vancouver, ISO, and other styles

12

García Luque, Manuel. "A próposito de un agente de Pedro de Mena en Lucena: El pintor Bernabé Ximénez de Illescas." Boletín de Arte, no. 32-33 (March 8, 2018): 281–310. http://dx.doi.org/10.24310/bolarte.2012.v0i32-33.4271.

Full text

Abstract:

Una relectura de la carta que el pintor lucentino Bernabé Ximénez de Illescas envió en marzo de 1669 al escultor Pedro de Mena nos permite revisar la figura del primero y reflexionar sobre las complejas redes clientelares del segundo, que permitieron el arribo de obras de su taller a ámbitos periféricos como Lucena, donde hacemos un repaso de su obra documentada y atribuida.

APA, Harvard, Vancouver, ISO, and other styles

13

Neroev, V. V. "MODERN ASPECTS OF DIABETIC RETINOPATHY AND DIABETIC MACULAR OEDEMA TREATMENT." Annals of the Russian academy of medical sciences 67, no. 1 (2012): 61–65. http://dx.doi.org/10.15690/vramn.v67i1.112.

Full text

Abstract:

Main reasons of eyesight deterioration in diabetic patients are diabetic retinopathy (DR) and diabetic macular oedema (DMO). International multicenter studies have shown that retinal laser coagulation in the event of DMO decreases the risk of eyesight loss in 50% , though only in 16% patients it was also possible to improve their eyesight. Use of vascular endothelial growth factor inhibitor – Ranibizumab – have opened a new era in DMA treatment. It’s efficacy and safety have been proven in several international studies. This article contains our own data upon the use of Lucentis in patients wi

APA, Harvard, Vancouver, ISO, and other styles

14

Quevedo Sánchez, Francisco Indalecio. "Juan Recio Aragonés, un judeoconverso entre la élite lucentina." Medievalismo, no. 27 (December 11, 2017): 259. http://dx.doi.org/10.6018/medievalismo.27.310661.

Full text

Abstract:

<p>En los últimos años se está superando la tradicional forma de estudiar al mundo judeoconverso, en la que la relación de la minoría con la Inquisición era el objeto principal de estudio, dejándose de lado la investigación de los confesos en sí mismos y de su integración social. Hoy sabemos que los cristianos nuevos no sólo sobrevivieron a persecuciones populares e institucionales, sino que lograron su total asimilación en todos los estratos de la sociedad. Ejemplos como el de la familia Aragonés muestran que muchos pasaron de la supervivencia al ennoblecimiento, no sin esfuerzo, no sin

APA, Harvard, Vancouver, ISO, and other styles

15

Bakri, Sophie J., Melissa R. Snyder, Joel M. Reid, Jose S. Pulido, Mohamed K. Ezzat, and Ravinder J. Singh. "Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)." Ophthalmology 114, no. 12 (2007): 2179–82. http://dx.doi.org/10.1016/j.ophtha.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Vander, J. F. "Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)." Yearbook of Ophthalmology 2008 (January 2008): 145–46. http://dx.doi.org/10.1016/s0084-392x(08)79091-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ratner, Mark. "Avastin as good as Lucentis." Nature Biotechnology 29, no. 7 (2011): 560. http://dx.doi.org/10.1038/nbt0711-560a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Bhardwaj, Tanu, Anurag S. Rathore, and Sandeep Kumar Jha. "The selection of highly specific and selective aptamers using modified SELEX and their use in process analytical techniques for Lucentis bioproduction." RSC Advances 10, no. 48 (2020): 28906–17. http://dx.doi.org/10.1039/d0ra03542d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Finger, Paul T. "Intravitreous Ranibizumab (Lucentis) for Radiation Maculopathy." Archives of Ophthalmology 128, no. 2 (2010): 249. http://dx.doi.org/10.1001/archophthalmol.2009.376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Vidinova, Christina Nicolaeva, Pravoslava Tz Gouguchkova, Tzvetomir Dimitrov, Kalin Nicolaev Vidinov, and Hristina Nocheva. "Ultrastruktureller und klinischer Vergleich des Ergebnisses bei PDR-Patienten, behandelt mit Ranibizumab oder Aflibercept – von Grundlagenforschungen zu den klinischen Therapien." Klinische Monatsblätter für Augenheilkunde 237, no. 01 (2019): 79–84. http://dx.doi.org/10.1055/a-0767-6951.

Full text

Abstract:

Zusammenfassung Hintergrund Die proliferative diabetische Retinopathie (PDR) ist eine der häufigsten Erblindungsursachen weltweit, in deren Verlauf sich sehr oft eine Glaskörperblutung als Komplikation entwickelt. Ziel unserer Untersuchung ist es, die ultrastrukturellen und klinischen Unterschiede bei entweder mit Ranibizumab oder mit Aflibercept behandelten PDR-Patienten zu vergleichen. Methoden In diese prospektive Untersuchung wurden 27 PDR-Patienten eingeschlossen. Bei 14 Patienten wurde Ranibizumab verwendet und mit Aflibercept wurden 13 Patienten behandelt. Bei 12 PDR-Patienten (6 von je

APA, Harvard, Vancouver, ISO, and other styles

21

TRAN, N. H., M. A. WILSON, A. S. MILEV, G. R. DENNIS, and G. S. K. KANNANGARA. "MECHANISM OF SILICA NANO-PLATE FORMATION FROM LUCENTITE." Surface Review and Letters 14, no. 02 (2007): 235–39. http://dx.doi.org/10.1142/s0218625x07009311.

Full text

Abstract:

The mechanism of formation of silica nano-plates by exfoliation of a phyllosilicate magnesium containing clay, Lucentite, in an aqueous solution of poly(acrylic acid) has been studied. Fourier transform infrared spectroscopy and Mg K -edge near edge X-ray adsorption fine structure (NEXAFS) analysis shows that non-surface (bulk) Mg ions were not chemically involved in the poly(acrylic acid)/clay intercalation, but were substantially involved in the exfoliation resulting in the silica nano-plates. During intercalation, O K -edge NEXAFS shows that surface defects were formed which represent addit

APA, Harvard, Vancouver, ISO, and other styles

22

Lorenz, Friederike. "Aufs Auge gedrückt." kma - Klinik Management aktuell 12, no. 11 (2007): 32–34. http://dx.doi.org/10.1055/s-0036-1574431.

Full text

Abstract:

Forschung ist die beste Medizin – doch was, wenn sie nicht bezahlbar ist? Die Pharmahersteller Roche und Novartis treiben derzeit ein böses Spiel mit der gesetzlichen Krankenversicherung und ihren Patienten. Lucentis, ein Augenarzneimittel, ist so teuer, dass den Kassen nur die illegale Erstattung eines anderen Medikaments oder den Erkrankten die Erblindung bleibt.

APA, Harvard, Vancouver, ISO, and other styles

23

Raftery, J., A. Clegg, J. Jones, S. C. Tan, and A. Lotery. "Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness." British Journal of Ophthalmology 91, no. 9 (2007): 1244–46. http://dx.doi.org/10.1136/bjo.2007.116616.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cohen, D. "Lucentis excluded from WHO list of essential medicines." BMJ 350, may13 9 (2015): h2573. http://dx.doi.org/10.1136/bmj.h2573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rosenfeld, Philip J. "Intravitreal Avastin: The Low Cost Alternative to Lucentis?" American Journal of Ophthalmology 142, no. 1 (2006): 141–43. http://dx.doi.org/10.1016/j.ajo.2006.03.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

. "1140 Lucentis® Nu Ook Bij PrivÉklinieken Vergoed." Zorg en Financiering 6, no. 9 (2007): 87. http://dx.doi.org/10.1007/bf03094432.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Wolf, A., A. Gandorfer, C. Haritoglou, C. Koller, A. Thalmeier, and A. Kampik. "Volumenberechnungen zur aktuellen intravitrealen Injektion von Lucentis®." Der Ophthalmologe 107, no. 5 (2009): 435–38. http://dx.doi.org/10.1007/s00347-009-2060-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Goodwin, Peter. "RANIBIZUMAB (LUCENTIS) VERSUS BEVACIZUMAB (AVASTIN): MODELING COST EFFECTIVENESS." Evidence-Based Ophthalmology 9, no. 1 (2008): 42–43. http://dx.doi.org/10.1097/ieb.0b013e31815f35e2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Boriskina, L. N., A. S. Zotov, A. S. Balalin, S. V. Balalin, Y. Y. Khzardzhan, and T. G. Efremova. "Results of complicated cataract surgery in patients with neovascular glaucoma in case of diabetic proliferative retinopathy or postthrombotic macular edema." Modern technologies in ophtalmology, no. 5 (October 20, 2021): 17–21. http://dx.doi.org/10.25276/2312-4911-2021-5-17-21.

Full text

Abstract:

Objective. To evaluate the results of complicated cataract surgery in patients with neovascular glaucoma in case of diabetic proliferative retinopathy or postthrombotic macular edema. Material and methods. A retrospective study of the complicated cataract surgery with IOL implantation results was performed in 38 patients (38 eyes) with neovascular glaucoma. The first stage was Lucentis intravitreal injection, then after 2 weeks intraocular pressure (IOP) under combined medical therapy was determined: 1) if IOP was <25 mm Hg, then phacoemulsification was performed; 2) if IOP remained >25

APA, Harvard, Vancouver, ISO, and other styles

30

Rouvas, A., P. Petrou, I. Ladas, G. Neamonitou, and I. Vergados. "Spontaneous Resolution of Vitreomacular Traction following Ranibizumab (Lucentis) Injection." European Journal of Ophthalmology 18, no. 2 (2008): 301–3. http://dx.doi.org/10.1177/112067210801800223.

Full text

Abstract:

Purpose Spontaneous resolution of vitreomacular traction syndrome in diabetic patients is a rare phenomenon that has been poorly described in the literature. Methods Case presentation. Results The authors present a case of spontaneous resolution of vitreomacular traction following intravitreal administration of ranibizumab. Conclusions In patients with vitreomacular traction syndrome and diabetic macular edema, the combination of the possible vitreous liquefaction and mechanical increase of vitreous volume caused by an intravitreal injection with a degree of reduction in retinal thickness caus

APA, Harvard, Vancouver, ISO, and other styles

31

Fletcher, E. C., and N. V. Chong. "Looking beyond Lucentis on the management of macular degeneration." Eye 22, no. 6 (2008): 742–50. http://dx.doi.org/10.1038/sj.eye.6703008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Michels, S., and P. J. Rosenfeld. "Therapie der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab/Lucentis™." Klinische Monatsblätter für Augenheilkunde 222, no. 06 (2005): 480–84. http://dx.doi.org/10.1055/s-2005-858315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lock, D. "Avastin and Lucentis: a guide through the legal maze." BMJ 350, apr01 13 (2015): h1377. http://dx.doi.org/10.1136/bmj.h1377.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Wise, J. "Lucentis offers treatment alternative for diabetic retinopathy, trial finds." BMJ 351, no. 16 4 (2015): h6145. http://dx.doi.org/10.1136/bmj.h6145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Lin, S., B. Z. George, and N. J. Wilson-Holt. "Intravitreal Ranibizumab (Lucentis) for Whole Brain Radiotherapy-induced Maculopathy." Clinical Oncology 26, no. 4 (2014): 236–38. http://dx.doi.org/10.1016/j.clon.2013.11.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Matthé, E., and D. Sandner. "Frühzeitige Behandlung mit Ranibizumab (Lucentis®) bei exsudativer AMD." Der Ophthalmologe 108, no. 3 (2010): 237–43. http://dx.doi.org/10.1007/s00347-010-2282-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kertes, Peter J. "RANIBIZUMAB (LUCENTIS) VS. BEVACIZUMAB (AVASTIN): THE DEBATE RAGES ON." Evidence-Based Ophthalmology 8, no. 4 (2007): 196–98. http://dx.doi.org/10.1097/ieb.0b013e318156a7d4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Lledó, Dolores, Manuel B. Crespo, and Juan Bta Amo-Marco. "In vitro multiplication ofVella lucentina M. B. crespo (Brassicaceae), a threatened Spanish endemic species." In Vitro Cellular & Developmental Biology - Plant 31, no. 4 (1995): 199–201. http://dx.doi.org/10.1007/bf02632021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gras, M. J., J. Raventós, A. Bonet, and D. A. Ramírez. "Análisis pluriescalar de los patrones de distribución espacial del endemisrno alicantino Vella Lucentina, MB Crespo (Brassicaceae) e implicaciones sobre su conservación." Geographicalia, no. 42 (June 21, 2016): 93. http://dx.doi.org/10.26754/ojs_geoph/geoph.2002421363.

Full text

Abstract:

El análisis de la distribución de los patrones espaciales y de la estructura de las poblaciones en el espacio, es uno de los aspectos clave que se deben considerar en la gestión y conservación de poblaciones de especies vegetales. En el presente estudio se realiza un análisis de la distribución del arbusto endémico estricto de la provincia de Alicante, Vella lucentina, con el fin de obtener información acerca de su biología que favorezca la gestión adecuada de las poblaciones existentes para asegurar su conservación. El estudio contempla dos escalas espaciales. En primer lugar, en la escala re

APA, Harvard, Vancouver, ISO, and other styles

40

Gallego-Pinazo, Roberto, Rosa Dolz-Marco, Cristina Marín-Lambíes, and Manuel Díaz-Llopis. "Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion." Ophthalmology and Eye Diseases 4 (January 2012): OED.S7264. http://dx.doi.org/10.4137/oed.s7264.

Full text

Abstract:

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

APA, Harvard, Vancouver, ISO, and other styles

41

Arias, Bernabeu, Carolina Arruabarrena Sánchez, Carlos Beckford, Agustín Martín Justicia, and Pedro Amat Peral. "Controversias en el Tratamiento con Anti-VEGF - Ranibizumab (Lucentis®)." Highlights of Vitreoretina 6, no. 4 (2013): 9–11. http://dx.doi.org/10.5005/hov-10102-06402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Jones, Jennifer. "Poster 35: Lucentis and Beyond: What Does the Future Hold?" Optometry - Journal of the American Optometric Association 79, no. 6 (2008): 315. http://dx.doi.org/10.1016/j.optm.2008.04.042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chen, J. J., S. E. Ebmeier, W. M. Sutherland, and N. G. Ghazi. "Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye." Eye 25, no. 11 (2011): 1504–11. http://dx.doi.org/10.1038/eye.2011.225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

PHAN, AP, DJ JACOBS, KB BOWMAN, and ZF FORSEY. "Comparison of Lucentis monotherapy vs. combination therapy for neovascular AMD." Acta Ophthalmologica 86 (September 4, 2008): 0. http://dx.doi.org/10.1111/j.1755-3768.2008.6448.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Querques, Giuseppe, Maria Cecilia Angulo Bocco, Gisele Soubrane, and Eric H. Souied. "Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease." Graefe's Archive for Clinical and Experimental Ophthalmology 246, no. 2 (2007): 319–21. http://dx.doi.org/10.1007/s00417-007-0689-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Yoon, Kyunghwan, and Antonios Kelarakis. "Nanoclay-Directed Structure and Morphology in PVDF Electrospun Membranes." Journal of Nanomaterials 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/367671.

Full text

Abstract:

The incorporation of organically modified Lucentite nanoclay dramatically modifies the structure and morphology of the PVDF electrospun fibers. In a molecular level, the nanoclay preferentially stabilizes the all-trans conformation of the polymer chain, promoting anαtoβtransformation of the crystalline phase. The piezoelectric properties of theβ-phase carry great promise for energy harvest applications. At a larger scale, the nanoclay facilitates the formation of highly uniform, bead-free fibers. Such an effect can be attributed to the enhanced conductivity and viscoelasticity of the PVDF-clay

APA, Harvard, Vancouver, ISO, and other styles

47

Horowitz, Soraya Alessandra, Nadyr P. Damasceno, and Eduardo F. Damasceno. "Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis®)." International Medical Case Reports Journal Volume 13 (February 2020): 27–32. http://dx.doi.org/10.2147/imcrj.s191654.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Manna, Avinash, Oluwatoyin Oyede, Brigid Ning, Yit Yang, and Niro Narendran. "Avastin and Lucentis: what do patients know? A prospective questionnaire survey." JRSM Short Reports 4, no. 9 (2013): 204253331348414. http://dx.doi.org/10.1177/2042533313484146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Kmietowicz, Z. "Minister rules out use of Avastin over Lucentis for wet AMD." BMJ 350, apr16 7 (2015): h2050. http://dx.doi.org/10.1136/bmj.h2050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rouvas, Alexander, Petros Petrou, Amalia Ntouraki, Maria Douvali, Ioannis Ladas, and Ioannis Vergados. "INTRAVITREAL RANIBIZUMAB (LUCENTIS) FOR BRANCH RETINAL VEIN OCCLUSION-INDUCED MACULAR EDEMA." Retina 30, no. 6 (2010): 893–902. http://dx.doi.org/10.1097/iae.0b013e3181cd4894.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!